Arnold Alper, MD
Nephrology · New Orleans, LANPI 1477509107
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,893 of the $4,195 with a category attached, or 69.0%. Aurinia Pharma U.S., Inc. accounts for 68.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $2,915 and has fallen 94.0% since, to $176 in 2025.
Across 41 payments — averaging $102.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$3K
- Vifor Pharma, Inc.$272
- GSK$270
- Travere Therapeutics, Inc.$246
- ANI Pharmaceuticals, Inc.$142
- Veloxis Pharmaceuticals, Inc.$57
- plus $348 from 13 others
What the payments were for
- Consulting fees$49512%
- Speaking & faculty fees$2,89369%
- Food & beverage$79319%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 5 | $2,860 |
| Vifor Pharma, Inc. | 5 | $272 |
| GSK | 3 | $270 |
| Travere Therapeutics, Inc. | 2 | $246 |
| ANI Pharmaceuticals, Inc. | 6 | $142 |
| Veloxis Pharmaceuticals, Inc. | 2 | $57 |
| BD | 1 | $53 |
| AstraZeneca(2 entities) | 3 | $52 |
| Cormedix Inc. | 3 | $48 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Biogen | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Bayer | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,195 in reported general payments places this provider in the 70th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 89 | $25,207 |
| ProcritEpoetin Alfa | 20 | $23,282 |
| Mycophenolic AcidMycophenolate Sodium | 46 | $16,461 |
| Envarsus XrTacrolimus | 22 | $12,029 |
| EliquisApixaban | 15 | $9,046 |
| Valganciclovir Hcl | 22 | $6,005 |
| Tacrolimus | 61 | $4,580 |
| Ketoconazole | 80 | $1,437 |
| Prednisone | 316 | $1,401 |
| Leflunomide | 26 | $996 |
| Labetalol Hcl | 12 | $994 |
| Calcitriol | 22 | $816 |
| Nifedipine ErNifedipine | 34 | $636 |
| Fluconazole | 24 | $591 |
| Amlodipine Besylate | 146 | $564 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New Orleans
- Juan Carlos VelezNew Orleans$282K
- Michael TouchyNew Orleans$56K
- Juan MedauraNew Orleans$14K
- Farshid YazdiNew Orleans$14K
- Mihran NaljayanNew Orleans$10K
- Rhea BhargavaNew Orleans$9K
- April FoxNew Orleans$8K
- Myra KleinpeterNew Orleans$7K
- Joshua LowentrittNew Orleans$7K
- Angela ReginelliNew Orleans$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.